ABBV Dec 2025 145.000 call
| Previous close | 22.97 |
| Open | 22.97 |
| Bid | 27.60 |
| Ask | 28.80 |
| Strike | 145.00 |
| Expiry date | 2025-12-19 |
| Day's range | 22.97 - 22.97 |
| Contract range | N/A |
| Volume | |
| Open interest | 161 |
PR NewswireRINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
AbbVie (NYSE: ABBV) today announced that RINVOQ® (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. Additionally, a new weight-based oral solution, RINVOQ® LQ (upadacitinib), is now available as an option for these pediatric popu
PR NewswireRefer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the debut of Refer a Friend, a new offering from Allē, the Allergan Aesthetics Loyalty Rewards Program. Now, Allē Members can invite their friends and family to join and both parties can receive savings on Allergan Aesthetics products or treatments from brands like BOTOX® Cosmetic (onabotulinumtoxinA), the JUVÉDERM® Collection of Fillers, SKINVIVE by JUVÉDERM®, CoolSculpting®, SkinMedica®, and DiamondGlow®.
ZacksAbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
In the most recent trading session, AbbVie (ABBV) closed at $160.19, indicating a -0.65% shift from the previous trading day.
